secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-10-20T10:35:29+00:00
Accession:  0001104659-26-117080
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quoin publishes peer-reviewed QRX003 paper; pediatric Netherton case clear at 21 months
--------------------------------------------------------------------------------

- Peer-reviewed paper in Dermatology and Therapy, published online Oct 13, 2026, introduces QRX003 and reports Prof. Alan Irvine's pediatric compassionate-use case.
- Pediatric Netherton patient on once-daily whole-body QRX003 improved IGA from 4 (severe) to 1 at six weeks and WI-NRS itch from 5 to 1.
- By eight months IGA was 0 (clear) and WI-NRS 0; over 21 months mostly IGA 0, off antihistamines, glucocorticoids and antivirals, no treatment-related adverse events.
- Phase 2/3 CL-QRX003-004 interim: 4 of 6 (66.7%) met primary IGA endpoint (p=0.0087 vs alpha 0.0215); full 20-patient enrollment targeted by end-2026, topline Q2 2027.
- Case is first pediatric use of QRX003 and longest continuous exposure to date; authors caution single-patient observations require trial confirmation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926117080/0001104659-26-117080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926117080/tm2627720d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-117080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer